In the Canadian Arctic territory of Nunavut, a landmark genomic study has revealed just how profoundly population-specific genetic variants can shape the health of young children. Researchers, working under the direction of Nunavut Tunngavik Incorporated and the Government of Nunavut Department of Health, genotyped newborn dried blood spots from nearly 3,000 infants born between January 1, 2010 and December 31, 2013, and then linked a subset of 2,206 Inuit children to health records spanning birth to five years of age. What they found was striking: three autosomal recessive conditions—IFNAR2 deficiency, primary ciliary dyskinesia caused by a DNAH11 variant, and congenital sucrase-isomaltase deficiency (CSID)—occur at live birth prevalences far exceeding anything documented in broader, admixed populations. The findings, published in BMC Pediatrics, underscore why genetic architecture unique to historically isolated populations demands population-informed screening, diagnosis, and care.
The technical logic behind the study rests on a well-established principle of population genetics. In small, historically endogamous populations, founder effects can elevate the frequency of otherwise rare disease alleles to levels where homozygosity becomes common. When two carriers of the same recessive variant have children, each pregnancy carries a 25 percent chance of producing an affected child. In admixed continental populations, such variants typically lurk at minor allele frequencies below one percent, making homozygous disease vanishingly rare. But in Nunavut, the numbers tell a different story. The SI c.273_274delAG variant, which abolishes the function of the sucrase-isomaltase enzyme needed to digest sucrose and starch, reached a carrier frequency of one in four, yielding an estimated live birth prevalence of one in 28 for CSID. The IFNAR2 c.157T>C variant, which disrupts the type I interferon receptor and leaves affected infants unable to mount innate antiviral responses, showed a carrier frequency of one in 18 and a live birth prevalence of one in 737. The DNAH11 c.4095+2C>A splice-site variant, responsible for a form of primary ciliary dyskinesia that impairs mucociliary clearance in the airways, appeared at a carrier frequency of one in 13 with a live birth prevalence of one in 1,474.
These are not abstract statistics. Each condition carries concrete, sometimes devastating consequences for infants and toddlers. IFNAR2 deficiency is perhaps the most dramatic: children who inherit two copies of the c.157T>C variant lack a functional receptor for type I interferons, the molecular alarm system that cells use to signal viral infection. The clinical consequence is extreme vulnerability to live attenuated viral vaccines—measles-mumps-rubella-varicella among them—because the weakened vaccine viruses, which a healthy immune system clears effortlessly, can cause severe disseminated disease in these children. The condition is functionally analogous to severe combined immunodeficiency in its implications for vaccination policy, yet it arises from a completely different molecular lesion and would be missed entirely by standard newborn screening for SCID, which relies on T-cell receptor excision circle (TREC) measurements that remain normal in IFNAR2-deficient infants. Identifying affected children before vaccination is therefore a matter of life and death, and the new prevalence estimate of one in 737 live births transforms the risk calculus for immunization programs across the territory.
Primary ciliary dyskinesia caused by the DNAH11 variant presents a different diagnostic challenge. The DNAH11 gene encodes a heavy-chain dynein motor protein essential for the beating motion of cilia, the microscopic hair-like structures that sweep mucus, bacteria, and debris out of the respiratory tract. When the c.4095+2C>A variant disrupts splicing of the gene’s transcript, ciliary motility fails, and affected children accumulate recurrent sinopulmonary infections, chronic wet cough, and neonatal respiratory distress. Without a high index of suspicion, PCD is frequently misdiagnosed as recurrent ordinary pneumonia or asthma, delaying the airway-clearance therapies and aggressive antibiotic strategies that preserve lung function. In a region where respiratory illness already places an outsized burden on pediatric health services and where medevac to southern tertiary centers is often the only route to specialized diagnostics, a prevalence of one in 1,474 live births means that PCD is no longer a zebra diagnosis but a realistic consideration for any Nunavut infant with unexplained neonatal respiratory distress or chronic productive cough.
The most numerically dominant condition, congenital sucrase-isomaltase deficiency, emerged from the study with particular clarity. Eighty-three children in the linked subset carried two copies of the SI c.273_274delAG variant, and their health records confirmed phenotypes consistent with the diagnosis. CSID impairs the brush-border enzymes of the small intestine that break down sucrose and starch, so affected infants develop chronic watery diarrhea, abdominal distension, failure to thrive, and irritability once sucrose and starches enter the diet—typically with the introduction of fruits, juices, and cereals in the first year of life. The symptoms mimic common conditions such as toddler’s diarrhea, cow’s milk protein allergy, and celiac disease, and affected children frequently undergo repeated investigations before the true cause is identified. The study’s quantitative analysis showed that CSID was associated with a significant increase in health care utilization for gastrointestinal illness visits before age two, with an odds ratio of 1.9 (95 percent confidence interval 1.2 to 3.0). In practical terms, children with two copies of the SI variant were nearly twice as likely to require health visits for gastrointestinal complaints during the toddler years, straining families and nursing stations alike.
Yet the study also delivered an unexpectedly hopeful finding. When the researchers examined the health visit patterns of CSID cases, they found that breastfeeding for up to six months was protective, associated with a reduced number of health care visits, with an odds ratio of 0.80 (95 percent confidence interval 0.63 to 1.0). The biological rationale is straightforward: breast milk contains virtually no sucrose or starch, so exclusively breastfed infants with CSID are spared exposure to the substrates their intestines cannot digest during the most vulnerable months of early life. The finding carries immediate public health relevance, reinforcing existing breastfeeding promotion efforts in Nunavut while adding a genetically informed dimension: for infants who later prove to have CSID, prolonged breastfeeding may meaningfully blunt the severity of early symptoms and reduce the cascade of medical encounters that otherwise accompanies diagnosis.
Methodologically, the study is notable for how it was conducted as much as for what it found. The research group combined local and national expertise, integrating Inuit governance through Nunavut Tunngavik Incorporated, the territorial Department of Health, the Qaujigiartiit Health Research Centre, and clinical and laboratory specialists from institutions including the Children’s Hospital of Eastern Ontario, Newborn Screening Ontario, the University of British Columbia, and the University of Manitoba. Dried newborn screening blood spots—already collected routinely from every infant—were genotyped, an approach that sidesteps the logistical barriers of recruiting families for fresh blood draws across scattered Arctic communities. A subset of genotyped children was then linked to a demographic and health database built from medical records spanning birth to five years, allowing the team to verify that genotypes predicted the clinical phenotypes expected for each condition. Live birth prevalence and carrier frequencies were first estimated across the full genotyped cohort of 2,947 infants and then recalculated for the linked subset, with the two approaches yielding consistent results.
The work also fits into a broader infrastructure effort. The genotyping and analysis were funded through the Silent Genomes Project, supported by Genome Canada, Genome BC, and the Canadian Institutes of Health Research, an initiative aimed at building an Indigenous Background Variant Library—a reference resource that catalogs benign and disease-associated variants in Indigenous populations so that clinical geneticists can distinguish pathogenic findings from population-specific benign variation. Without such reference data, Indigenous patients undergoing clinical genome sequencing face a disproportionate burden of variants of uncertain significance, a problem the Nunavut study directly helps to address by documenting which variants in this population are common, expected, and, when homozygous, clinically consequential.
The authors’ conclusion is unambiguous: genetic testing, practitioner education, and Inuit-informed management strategies are urgently needed to address these conditions and improve outcomes. For IFNAR2 deficiency, that means developing pathways to identify affected infants before they receive live attenuated viral vaccines, potentially through carrier screening or targeted newborn testing, and educating immunization providers across the Arctic. For PCD, it means lowering the diagnostic threshold for referral to ciliary function testing in infants with compatible respiratory histories. For CSID, it means recognizing that a child in Nunavut with chronic diarrhea and failure to thrive has roughly a one-in-28 baseline likelihood of the condition—odds that justify empirical trials of sucrase enzyme replacement or sucrose-restricted diets far earlier than would be considered elsewhere. Each of these interventions is inexpensive relative to the costs of delayed diagnosis, repeated medevacs, and preventable morbidity.
Beyond Nunavut, the study sends a message to genomic medicine worldwide. Reference genomes, variant databases, and screening panels built predominantly on European-ancestry populations systematically underperform for everyone else, and the Inuit case demonstrates the scale of the blind spot: three recessive conditions, each effectively invisible in generic screening programs, collectively affecting on the order of one in 25 live births in this cohort when CSID’s high prevalence is included. Population-specific genomics, governed by and conducted with the communities it describes, is not a niche academic exercise—it is the difference between a health system that anticipates the diseases its children actually carry and one that discovers them one crisis at a time. The Nunavut cohort study provides both the evidence and, increasingly, the template for how such work should be done.
Subject of Research: Population-specific autosomal recessive genetic variants and their child health impacts in Inuit children in Nunavut
Article Title: Population-specific genetic variants and related health outcomes in a cohort of Inuit children in Nunavut
Article References: Gonzalez-Lema, J., Allen, J., Agyemang, E., Patterson, M., Miners, A., Sheffield, H., Caughey, A., Pham-Huy, A., Kovesi, T., Shapiro, A. J., Kernohan, K., Yeh, E., Yeh, A., Mears, A., Lacaria, M., Collins, S., Braschel, M., Marcadier, J., Otley, A., … Arbour, L. (2026). Population-specific genetic variants and related health outcomes in a cohort of Inuit children in Nunavut. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07720-7
Image Credits: AI Generated
DOI: 10.1186/s12887-026-07720-7
Keywords: Inuit, Nunavut, genetic variants, IFNAR2 deficiency, primary ciliary dyskinesia, DNAH11, congenital sucrase-isomaltase deficiency, founder effects, newborn screening, autosomal recessive, child health, Indigenous genomics
News Source: Juliet Wilcox. (October 10, 2026). Hidden Genetic Burden: Three Rare Diseases Shape Child Health in Nunavut. Scienmag.
